Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of rosuvastatin 20 mg tablets versus Crestor 20 mg in healthy Thai volunteers under fasting conditions
TCTR20180802003Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rosuvastatin in hypercholesterolemia, combined dyslipidaemia and cardiac morbidity (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
rosuvastatin
03
Conditions
hypercholesterolemiacombined dyslipidaemiacardiac morbidity
Beyond the preview
Go deeper on TCTR20180802003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180802003.